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Scientific Trials—In the Laboratories,
Not the Courts
In 2015, one of us published a peer-reviewed study,
together with colleagues at the University of California,
San Francisco, replicating prior research from the US
Food and Drug Administration (FDA) detecting a designer stimulant, β-methylphenylethylamine, in sports,
weight loss, and “cognitive function” supplements sold
in the United States.1,2 The confirmatory study prompted
the FDA to take enforcement action against companies
selling the stimulant as a dietary ingredient.3
One of the companies that received an FDA warning letter sued the study’s authors for $200 million in
damages for libel, claiming, without supporting scientific evidence, that multiple statements in the article were
false.4 Following intrusive discovery and a 7-day jury trial
in federal court, a Massachusetts jury rejected the company’s claims and entered a verdict in the authors’ favor.5
The case is just a recent example of using litigation
to target scientists. In 2008, the manufacturer of a hip
protector sued a Harvard researcher for commercial disparagement over a study published in JAMA demonstrating that the hip protector did not prevent fractures.6
In 2012, the chief executive officer of a pharmaceutical
company sued a researcher who chaired his data monitoring committee after the researcher published an article in Annals of Internal Medicine explaining how the
CEO mischaracterized study results.7 (The CEO was later
convicted of wire fraud.) And, in 2013, a biomarker company sued a group of scientists and an academic journal, Clinical Chemistry, for publishing a study suggesting that the company’s assay was insufficiently
sensitive.8
In all of these cases, the research in question was vetted through peer review and published in reputable journals. Aggrieved executives, however, may not use the
conventional approaches to challenging research findings: publishing rebuttals, writing letters to the editor,
replicating studies, and the like. Instead, whether
through discovery or subpoenas, plaintiffs’ lawyers may
probe scientists’ private communications, which they
may then try to exploit to suggest that the research was
biased, unethical, or vindictive.
When lawsuits target scientists, it does not matter
that plaintiffs almost never win. It does not even matter if the case goes to trial. The goal is to intimidate. In
the lawsuit over dietary supplements, for example, the
head of the company who brought the suit openly admitted that he was “hoping that we were able to silence
this guy,”5 as well as other researchers who might raise
questions about the supplement industry. The most
frivolous lawsuit can generate substantial legal costs, distract scientists from research, force the indiscriminate
disclosure of laboratory notebooks and emails, and create unnecessary stress for colleagues and families.
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Just the possibility of litigation casts a shadow.
Young researchers may shy away from fields that could
make them targets. Universities might quietly discourage work that could embroil them in expensive litigation. Scientists may explicitly avoid lines of inquiry into
the safety and value of commercial products—the very
research that could make an immediate difference in
people’s lives.
Lawyers and judges sometimes resist the idea of singling out a category of litigation for special condemnation. They worry in particular about infringing on the right
of access to the courts for redress of legitimate grievances. But lawsuits brought to harass researchers raise
concerns above and beyond the ordinary case. These
concerns are not new. As a federal appeals court noted
in 1982, litigation “inevitably tends to check the ardor and
fearlessness of scholars, qualities at once so fragile and
so indispensable for fruitful academic labor.”9
It is not just scientists who suffer from abusive lawsuits—it is science itself.
That is why it is crucial for judges to quickly dispose
of meritless lawsuits filed for the purpose of discouraging research. They have any number of tools to do so.
As the Supreme Court has held, courts need not accept
vague allegations of conspiracy, bias, or conflicts of
interest.10 They should respect state-law privileges that
protect researchers from lawsuits over scientific speech.
When appropriate, any discovery should be carefully circumscribed and overseen. Judges should zealously apply laws, on the books in more than half the states, that
allow for the rapid dismissal of strategic lawsuits against
public participation (SLAPP). These anti-SLAPP statutes, which typically allow defendants to recover their
attorneys’ fees, discourage the filing of meritless lawsuits that serve no other purpose than to silence opposing points of view.
Moreover, courts should not allow lawsuits to proceed to trial solely on the basis of warring affidavits over
a study’s soundness or conclusions. It is easy to find “experts”—typically paid hourly rates—who are willing to present a contrary opinion or second-guess a study, allowing the plaintiff to claim there are “disputed facts” that
must be submitted to a full trial. But a researcher can be
held legally responsible for making false statements only
when he or she is deliberately lying, knows the statement to be false, or is reckless about the truth of what
is being said. Such malfeasance is uncommon enough
that, absent concrete evidence to the contrary, alleged
lapses in scientific judgment should not be taken as evidence of academic fraud.
When there are concerns that errors and mistakes
may be evidence of academic fraud, they should be
addressed through the regular academic channels.
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Universities should be contacted and asked to investigate, as
should journal editors. There are mechanisms for faculty and
research review. And should evidence of fraud be unearthed—
such as the falsification of data or the knowing misrepresentation
of results—courts could at that point allow legal cases to proceed.
In general, however, the courtroom is not the place to resolve scientific disputes.
Finally, courts should do more to discourage abusive lawsuits
from being brought in the first place. At a minimum, plaintiffs should
bear their opponents’ attorneys’ fees. Courts can go further, though.
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They should also consider sanctioning attorneys who are unethical
enough to represent clients whose only goal is to discourage science. Judges can publicly reprimand lawyers, refer them for disciplinary action to the bar, and even impose monetary sanctions. If attorneys recognized that frivolous, antiscience litigation will be dealt
with harshly, they might be more likely to turn away clients that aim
to silence researchers whose findings they dislike.
The laboratory and the court are both truth-seeking institutions, but they do not mix well. In doing their work, courts should
give scientists space to do theirs.
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